Navigation Links
Clinical trial for dry mouth funded by international oral care award
Date:3/16/2011

AUGUSTA, Ga. A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.

"These patients' mouths are as dry as if you've closed the faucet, and we want to turn that faucet back on," said Dr. Stephen Hsu, Molecular and Cell Biologist and co-investigator of the study. "The cells and glands that produce saliva are still there, they're just not working."

Through previous animal studies and human sample testing, GHSU researchers found that dry mouth involves salivary gland inflammation, fewer antioxidants and elevated markers for abnormal growth and DNA damage caused by free radicals. Powerful antioxidants in green tea, called polyphenols, reduce that damage to the salivary gland.

"With green tea polyphenols, we have an agent that's helping to correct the salivary gland's abnormal behavior," said Dr. Douglas Dickinson, Associate Professor in the Department of Oral Biology and co-investigator.

The team formulated an all-natural lozenge containing green tea polyphenols, xylitol and jaborandi leaf extract, a plant used in South and Central America to promote saliva production. The lozenge offers a slow, extended release only in the mouth, not the systemic effect caused by prescription dry-mouth medication, which can prompt side effects such as diarrhea and excessive sweating, said Dr. Scott De Rossi, Chairman of the Department of Oral Health and Diagnostic Sciences and principal investigator.

Sixty patients will be followed during the eight week trial, with half taking the lozenge and half taking a placebo. The four daily doses of the lozenge taken during the trial are equivalent to drinking four or five cups of green tea, which benefits overall health, the researchers added.

"I think the promise here is that patients are going to feel better and we're going to see some improvement not only in how their salivary glands function and how their mouth feels, but also how the glands look on a cellular level," De Rossi said. The hope is that the lozenge's effects will last for hours after it has dissolved.

For their efforts, he and his GHSU co-investigators, Drs. Dickinson, Hsu, Stephen Looney and Kalu Ogbureke, have received one of three International Innovation in Oral Care Awards sponsored by the International Association of Dental Research and GlaxoSmithKline.

The $75,000 award, presented today at the 89th General Session and Exhibition of the International Association of Dental Research in San Diego, advances research that directly benefits the public's oral health. The initial part of the study was funded by a $50,000 grant from the Georgia Research Alliance.

Xerostomia, or dry mouth, can be caused by autoimmune disorders such as Sjogren's syndrome, chronic medication use, uncontrolled diabetes and cancer therapies. It can cause bad breath, advanced periodontal disease, mouth ulcers, discomfort, trouble speaking and swallowing and a burning sensation at night.


'/>"/>

Contact: Paula Hinely
phinely@georgiahealth.edu
706-721-3646
Georgia Health Sciences University
Source:Eurekalert

Related medicine news :

1. Revitalizing Cancer Clinical Trials -- March 21 symposium
2. Novel clinical trial aims to reduce recurrence of aggressive breast cancer
3. Clinical observation leads to lung cancer discovery
4. Study reveals security weaknesses in file-sharing methods used in clinical trials
5. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
6. Elsevier/MEDai enhances real-time clinical surveillance system for hospitals
7. Few physicians refer patients to cancer clinical trials
8. Older adults often excluded from clinical trials
9. New clinical trial to determine ovarian cancer risks in African-American women
10. Case Western Reserve/University Hospitals join nationwide HIV vaccine clinical trial
11. Most Guidelines for Infectious Diseases Dont Come From Clinical Trial Findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: